CN109652380A - 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 - Google Patents
基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 Download PDFInfo
- Publication number
- CN109652380A CN109652380A CN201910075913.2A CN201910075913A CN109652380A CN 109652380 A CN109652380 A CN 109652380A CN 201910075913 A CN201910075913 A CN 201910075913A CN 109652380 A CN109652380 A CN 109652380A
- Authority
- CN
- China
- Prior art keywords
- cell
- car
- lewisy
- seq
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 65
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 55
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 41
- 238000003209 gene knockout Methods 0.000 claims abstract description 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 230000008685 targeting Effects 0.000 claims abstract description 11
- 239000013600 plasmid vector Substances 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims description 38
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000005611 electricity Effects 0.000 claims description 11
- 238000005457 optimization Methods 0.000 claims description 11
- 238000001890 transfection Methods 0.000 claims description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 8
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 8
- 108010020764 Transposases Proteins 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 108091033409 CRISPR Proteins 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims description 4
- 102000014128 RANK Ligand Human genes 0.000 claims description 4
- 108010025832 RANK Ligand Proteins 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 4
- -1 ZFN Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000008676 import Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000031146 intracellular signal transduction Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 229950010131 puromycin Drugs 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 101710145634 Antigen 1 Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 2
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 238000010459 TALEN Methods 0.000 claims description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000003151 transfection method Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 8
- 238000011084 recovery Methods 0.000 description 7
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 101150116295 CAT2 gene Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 101100126846 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) katG gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical group O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000001978 tetrosyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910075913.2A CN109652380B (zh) | 2019-01-25 | 2019-01-25 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910075913.2A CN109652380B (zh) | 2019-01-25 | 2019-01-25 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109652380A true CN109652380A (zh) | 2019-04-19 |
CN109652380B CN109652380B (zh) | 2023-04-28 |
Family
ID=66121575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910075913.2A Active CN109652380B (zh) | 2019-01-25 | 2019-01-25 | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109652380B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112239769A (zh) * | 2019-07-19 | 2021-01-19 | 华东师范大学 | 一种引导PD1基因切割实现外源序列高效整合的sgRNA |
WO2022052877A1 (zh) * | 2020-09-10 | 2022-03-17 | 上海邦耀生物科技有限公司 | 对细胞中的靶位点进行基因编辑的方法 |
CN114231559A (zh) * | 2020-09-09 | 2022-03-25 | 广西医科大学 | 含有car核酸片段的表达质粒、含该表达质粒的靶向cd105的car-t细胞及其制备方法和应用 |
CN114807155A (zh) * | 2021-01-18 | 2022-07-29 | 华东师范大学 | 用于基因编辑的组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107119021A (zh) * | 2017-07-04 | 2017-09-01 | 王小平 | Pd‑1敲除cd19car‑t细胞的制备 |
WO2017193107A2 (en) * | 2016-05-06 | 2017-11-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
CN107338224A (zh) * | 2017-07-04 | 2017-11-10 | 成都克里斯博生物科技有限公司 | PD‑1敲除EGFRvIIICAR‑T细胞的制备 |
CN107586777A (zh) * | 2016-07-08 | 2018-01-16 | 上海吉倍生物技术有限公司 | 人PDCD1基因sgRNA的用途及其相关药物 |
CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
-
2019
- 2019-01-25 CN CN201910075913.2A patent/CN109652380B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017193107A2 (en) * | 2016-05-06 | 2017-11-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
CN107586777A (zh) * | 2016-07-08 | 2018-01-16 | 上海吉倍生物技术有限公司 | 人PDCD1基因sgRNA的用途及其相关药物 |
CN107119021A (zh) * | 2017-07-04 | 2017-09-01 | 王小平 | Pd‑1敲除cd19car‑t细胞的制备 |
CN107338224A (zh) * | 2017-07-04 | 2017-11-10 | 成都克里斯博生物科技有限公司 | PD‑1敲除EGFRvIIICAR‑T细胞的制备 |
CN108913718A (zh) * | 2018-07-20 | 2018-11-30 | 苏州茂行生物科技有限公司 | 一种靶向EGFR vⅢ的CAR-T细胞的制备方法及应用 |
Non-Patent Citations (5)
Title |
---|
FAN ET AL.: "Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 * |
NEESON ET AL.: "Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype", 《GENE THERAPY》 * |
PEINERT ET AL.: "Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen", 《GENE THERAPY》 * |
RITCHIE ET AL.: "Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia", 《THE AMERICAN SOCIETY OF GENE & CELL THERAPY》 * |
RUPP ET AL.: "CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells", 《SCIENTIFIC REPORTS》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112239769A (zh) * | 2019-07-19 | 2021-01-19 | 华东师范大学 | 一种引导PD1基因切割实现外源序列高效整合的sgRNA |
CN112239769B (zh) * | 2019-07-19 | 2023-11-07 | 上海邦耀生物科技有限公司 | 一种引导PD1基因切割实现外源序列高效整合的sgRNA |
CN114231559A (zh) * | 2020-09-09 | 2022-03-25 | 广西医科大学 | 含有car核酸片段的表达质粒、含该表达质粒的靶向cd105的car-t细胞及其制备方法和应用 |
WO2022052877A1 (zh) * | 2020-09-10 | 2022-03-17 | 上海邦耀生物科技有限公司 | 对细胞中的靶位点进行基因编辑的方法 |
CN114807155A (zh) * | 2021-01-18 | 2022-07-29 | 华东师范大学 | 用于基因编辑的组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109652380B (zh) | 2023-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109652380A (zh) | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 | |
CN106544321B (zh) | 通用型car-t细胞及其制备方法和用途 | |
CN109706121A (zh) | 一种基于碱基编辑的通用型car-t细胞及其制备方法和应用 | |
CN108531457A (zh) | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 | |
CN111194350A (zh) | 一种基因编辑t细胞及其用途 | |
CN109750035B (zh) | 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA | |
CN109735500A (zh) | 一种分泌型靶向cd133的car-t细胞及其制备方法和应用 | |
CN109678965A (zh) | 嵌合抗原受体及其基因和重组表达载体、cd22-cd19双靶向性的t细胞及其应用 | |
CN109136248A (zh) | 多靶点编辑载体及其构建方法和应用 | |
WO2022078153A1 (zh) | 一种用基因编辑改造原代细胞的dna模板及定点插入方法 | |
CN104910278B (zh) | 一种用于制备cart细胞的具有高效转染能力和生物学活性的慢病毒 | |
CN114085841B (zh) | 一种cho细胞基因nw_003614092.1内稳定表达蛋白质的位点及其应用 | |
CN108103105A (zh) | 一种car-t细胞的制备方法、制得的car-t细胞及其应用 | |
CN110257429A (zh) | 重组表达载体、靶向性的t细胞及它们的应用 | |
KR20220097984A (ko) | 키메라 항원 수용체를 발현하는 t 세포를 제조하기 위한 제조 방법 | |
JP2023541028A (ja) | 細胞内の標的部位を遺伝子編集する方法 | |
CN113122503A (zh) | 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用 | |
CN114058625A (zh) | 一种cho细胞基因nw_003613781.1内稳定表达蛋白质的位点及其应用 | |
CN101245106B (zh) | 抗vegf受体单克隆抗体及其制备方法和应用 | |
CN108467864A (zh) | 一种icam-1基因敲除肿瘤细胞株及其应用 | |
CN112105720A (zh) | 一种基因工程化的免疫淋巴细胞及其制备方法 | |
CN111983218A (zh) | 一种用于检测活细胞-活细胞表面受体-配体相互作用的试剂盒 | |
US20230054266A1 (en) | Method for purifying ucart cell and use thereof | |
CN113122504A (zh) | 一种纯化ucart细胞的方法与应用 | |
CN106636155A (zh) | Cd19‑car基因序列在恶性b细胞肿瘤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 127, Building 3, No. 6 Kecheng Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: SUZHOU MAXIMUM BIO-TECH Co.,Ltd. Address before: Unit 304, A4 Building, Biomedical Industrial Park, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province, 215000 Patentee before: SUZHOU MAXIMUM BIO-TECH Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 202 and Room 203, Unit 201, Building 4, Zone B, Phase III, Biopharmaceutical Industry Park, No. 99 Jingu Road, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province, 215024 Patentee after: SUZHOU MAXIMUM BIO-TECH Co.,Ltd. Country or region after: China Address before: Room 127, Building 3, No. 6 Kecheng Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee before: SUZHOU MAXIMUM BIO-TECH Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |